AbstrakKanker serviks merupakan jenis kanker dengan kasus kedua terbanyak di Rumah Sakit Umum Pusat Dr. Hasan Sadikin (RSHS) dan 82% di antaranya merupakan stadium II dan III. Terapi yang direkomendasikan untuk kanker serviks stadium IIB-IIIB menurut Pedoman Nasional Pelayanan Kedokteran (PNPK) kanker serviks adalah kemoradiasi atau radioterapi. Tujuan penelitian ini adalah untuk memberikan gambaran profil penatalaksanaan kanker serviks stadium IIB-IIIB dengan radioterapi dan kemoradiasi di RSHS pada tahun 2015-2017. Penelitian ini merupakan penelitian observasional dengan metode potong lintang. Pengambilan data dilakukan secara retrospektif dari rekam medik pasien di Instalasi Onkologi Radiasi dan Sistem Informasi Rumah Sakit (SIRS) RSHS dengan kriteria inklusi pasien dewasa berusia lebih dari 18 tahun, memiliki data klinis dan data terapi yang lengkap serta tidak memiliki penyakit penyerta. Data yang diperoleh dianalisis secara deskriptif dan secara statistik dengan uji Kruskal Wallis untuk data numerik serta uji Chi-Square dan uji Fisher's Exact untuk data kategorik. Terdapat 234 data pasien yang memenuhi kriteria. Sebanyak 94,01% pasien berasal dari Jawa Barat, 86,1% merupakan ibu rumah tangga dan 63,6% mengenyam pendidikan hingga tingkat Sekolah Dasar. Radioterapi merupakan terapi yang lebih banyak diberikan kepada pasien dengan dosis total sekitar 6700-7200cGy dan ratarata lama terapi selama 14 minggu. Rata-rata waktu yang diperlukan pasien untuk mendapatkan terapi setelah mendaftar untuk terapi sekitar 7 minggu. Regimen kemoterapi sisplatin merupakan regimen pilihan utama yang diberikan pada pasien dengan kemoradiasi dengan frekuensi 1-5 kali pemberian. Efek samping yang paling sering terjadi pada terapi kanker serviks baik dengan radioterapi maupun kemoradiasi adalah mual dan muntah. Analisis efektivitas biaya akan dilakukan pada penelitian selanjutnya untuk mengetahui terapi mana yang lebih baik dari segi efektivitas terapi dan biaya. AbstractCervical cancer is a type of cancer with the second most cases at Dr. Hasan Sadikin General Hospital (RSHS) Bandung and 82% of those cases are stage II and III. Recommended therapy for cervical cancer stage IIB-IIIB according to the National Medical Services guidelines for cervical cancer (PNPK) is chemoradiation or radiotherapy. The purpose of this study was to provide an overview of the management profile of stage IIB-IIIB cervical cancer with radiotherapy and chemoradiation at RSHS in 2015-2017. This study was an observational study with a cross-sectional method. Retrospective data collection was carried out from medical records of patients in Radiation Oncology Installation and Hospital Information System (SIRS) with inclusion criteria of adult patient with over 18 years of age, having complete clinical and therapeutic data and not having any comorbidities. Obtained data were analyzed descriptively and statistically with Kruskal Wallis test for numerical data and Chi-Square test and Fisher's Exact test for categorical data. A total of 234 patients' data met the ...
Purpose Cervical cancer is the second most common type of cancer and cause of death from cancer in Indonesia. In 2013, cervical cancer was the most prevalent cancer in Indonesia, with a rate of 0.8 per 1000 women. Based on the National Guidelines for Cervical Cancer Medical Services in Indonesia, the recommended therapy for stages IIB-IIIB cervical cancer is chemoradiation or radiotherapy. This study aimed to evaluate the cost-effectiveness of chemoradiation and radiotherapy for treating stage IIB-IIIB cervical cancer in a national referral hospital in Indonesia. Patients and Methods A cross-sectional study from a healthcare perspective using retrospective patient data was conducted. The included patients had stage IIB-IIIB registered cervical cancer, were in the hospital between January 1, 2015 and December 31, 2017, received chemoradiation or radiotherapy, were ≥18 years old, and had complete clinical data and detailed cost of therapy data. The incremental cost-effectiveness ratio (ICER) were calculated, and a sensitivity analysis was performed. Results The average treatment cost per patient was $2944 and $3231 for radiotherapy and chemoradiation, respectively. Despite the fact that the treatment effectiveness of chemoradiation (69.1%) was considered to be higher than that of radiotherapy (63.2%), chemoradiation had more potential side effects than radiotherapy. In a comparison with radiotherapy, the ICER of chemoradiation was $48.6 per complete response rate. Additionally, the cost of radiotherapy was the most influential parameter impacting the ICER. Conclusion Chemoradiation was considered to be more costly than radiotherapy. Additionally, the effectiveness of chemoradiation was higher than that of radiotherapy. A cost utility analysis (CUA) is required for further investigation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.